The results of the present study indicated that the efficacy of treating 39 HER-2-overexpressing breast cancer patients with the TEC regimen was most favorable, demonstrating 94.9% OS and 69.2% pCR rates after six cycles of observation. This evidence concerns the gene ERBB2 and breast carcinoma.